Re-evaluation of lipiodolized transarterial chemoembolization therapy for intrahepatic recurrence of hepatocellular carcinoma after curative liver resection

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 15, Issue 6, 2008, Pages 627-633

  Eguchi, Susumu ^a   Matsumoto, Shigehiro ^a   Hamasaki, Koji ^a   Takatsuki, Mitsuhisa ^a   Hidaka, Masaaki ^a   Tajima, Yoshitsugu ^a   Sakamoto, Ichiro ^a   Kanematsu, Takashi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Hepatocellular carcinoma; Lipiodolized chemoembolization; Recurrence; Resection

Indexed keywords

EPIRUBICIN; GELFOAM; IODINATED POPPYSEED OIL; MITOMYCIN C;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; FEMALE; HUMAN; INFLAMMATION; LIPIODOLIZED TRANSARTERIAL CHEMOEMBOLIZATION; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HEPATECTOMY; HUMANS; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 56249139366     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-007-1341-3     Document Type: Article

References (23)

1. Eguchi S, Ijtsma AJ, Slooff MJ, Porte RJ, de Jong KP, Peeters PM, et al. Outcome and pattern of recurrence after curative resection for hepatocellular carcinoma in patients with a normal liver compared to patients with a diseased liver. Hepatogastroenterology 2006:53;592-596.
2. Nicoli N, Casaril A, Marchoiori I, Mangiante G, Hasheminia AR. Treatment of recurrent hepatocellular carcinoma by radiofrequency thermal ablation. J Hepatobiliary Pancreat Surg 2001;8:417-421.
3. Poon RT, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000;232:10-24.
4. Maluccio M, Covey AM, Gandhi R, Gonen M, Getrajdman GI, Brody LA, et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol 2005;16:955-961.
5. Kanematsu T, Takenaka K, Matsumata T, Furtuta T, Sugimachi K, Inokuchi K, et al. Limited hepatic resection effective for selected cirrhotic patients with primary liver cancer. Ann Surg 1984;199:51-56.
6. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet 2002;359:1734-1739.
7. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469.
8. Ueno S, Tanabe G, Nuruki K, Oketani M, Komorizono Y, Hokotate H, et al. Prognosis of hepatocellualr carcinoma associated with Child class B and cirrhosis in relation to treatment: A multivariate analysis of 411 patients in at a single center. J Hepatobiliary Pancreat Surg 2002;9:1164-1171.
9. Kanematsu T, Matsumata T, Takenaka K, Yoshida Y, Higashi H, Sugimachi K, et al. Clinical management of recurrent hepatocellular carcinoma after primary resection. Br J Surg 1988;75:203-206.
10. Kanematsu T, Furuta T, Takenaka K, Matsumata T, Yoshida Y, Nishizaki T, et al. A 5-year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 1989;10:98-102.
11. Kanematsu T, Inokuchi K, Sugimachi K, Furuta T, Sonoda T, Tamura S, et al. Selective effects of lipiodolized antitumor agents. J Surg Oncol 1984;25:218-226.
12. Furuta T, Kanematsu T, Matsumata K, Shirabe K, Yamagata M, Utsunomiya T, et al. Lipiodolization prolongs survival rates in postoperative patients with a recurrent hepatocellular carcinoma. Hepatogastroenterology 1990;37:494-497.
13. Covey AM, Maluccio MA, Schubert J, BenPorat L, Brody LA, Sofocleous CT, et al. Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. Cancer 2006;106:2181-2189.
14. Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, et al. Surgery for small liver cancers. Semin Surg Oncol 1993;9:298-304.
15. The Liver Cancer Study Group of Japan. Classification of primary liver cancer. First English edition. Tokyo: Kanehara; 1997.
16. Sobin LH, Wittekind C, editors. TMN classification of malignant tumours. 5 th ed. New York: Wiley; 1997.
17. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
18. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
19. Okazaki M, Yamasaki S, Ono H, Higashihara H, Koganemaru F, Kimura S, et al. Chemotherapy for recurrent hepatocellular carcinoma in the residual liver after hepatectomy. Hepatogastroenterology 1993;40:320-323.
20. Lee PH, Lin WJ, Tsang YM, Hu RH, Sheu JC, Lai MY, et al. Clinical management of recurrent hepatocellular carcinoma. Ann Surg 1995;222:670-676.
21. Park JH,. Han JK, Chung JW, Han MC, Kim ST. Postoperative recurrence of hepatocellular carcinoma: Results of transcatheter arterial chemoembolization. Cardiovasc Intervent Radiol 1993;16:21-24.
22. Imaoka S. Sasaki Y, Masutani S, Furukawa H, Ishikawa O, Kabuto T, et al. Palliative surgical treatment for recurrent and non-resectable hepatocellular carcinoma. Hepatogastroenterology 1993;40:342-346.
23. Poon RT, Ngan H, Lo CM, Liu CL, Fan ST, Wong J. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000;73:109-114.